<- Go Home

Harvard Apparatus Regenerative Technology Inc.

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company also sells Longevity products that focuses on personal healthcare, including longevity dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.

Market Cap

$61.3M

Volume

6.3K

Cash and Equivalents

$139.0K

EBITDA

-$7.4M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$167.0K

Profit Margin

77.31%

52 Week High

$6.00

52 Week Low

$2.13

Dividend

N/A

Price / Book Value

-190.05

Price / Earnings

-6.77

Price / Tangible Book Value

-190.05

Enterprise Value

$61.7M

Enterprise Value / EBITDA

-8.45

Operating Income

-$7.5M

Return on Equity

454.59%

Return on Assets

-124.05

Cash and Short Term Investments

$139.0K

Debt

$568.0K

Equity

-$290.0K

Revenue

$216.0K

Unlevered FCF

-$2.8M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches